Dec 06, 2018 - Impressive list of collaborators, including Genentech, Merck, Nektar Therapeutics, Columbia University and MD Anderson Cancer Center; and strong balance sheet with ~$139 million in cash.Breakout ASH20
Dec 05, 2018 -
Nov 16, 2018 - Under its Real-Time Oncology Review (RTOR) program, the FDA approves Seattle Genetics' (SGEN +2.2%) ADCETRIS (brentuximab vedotin), combined with chemo, for the treatment of adult patients wit
Nov 15, 2018 - Most Biotech Developers group are in a pullback mode, reflecting the market’s current election uncertainties.The Direxion Daily S&P Biotech Bull 3X ETF (LABU) holds many of these stocks and is an effi
Nov 15, 2018 - Seattle Genetics (NASDAQ:SGEN) is up 2% premarket, albeit on only 200 shares, in response to its announcement that the FDA has granted Breakthrough Therapy status for ADCETRIS (brentuximab vedotin) f
Oct 26, 2018 - Seattle Genetics' (SGEN) loss matches estimates but rides high on revenue beat in Q3.
Oct 26, 2018 - SGEN earnings call for the period ending September 30, 2018.
Oct 25, 2018 - Seattle Genetics, Inc. (NASDAQ:SGEN)Q3 2018 Earnings CallOctober 25, 2018 4:30 pm ETExecutivesPeggy Pinkston - Seattle Genetics, Inc.Clay B. Siegall - Seattle Genetics, Inc.Darren S. Cline - Seattle G
Oct 25, 2018 - Stocks
staged a welcome rebound on Thursday, but not before giving up some gains in
the last hour. R
Sep 21, 2018 - The Japanese Ministry of Health, Labor and Welfare approves Seattle Genetics' (SGEN -1.4%) ADCETRIS (brentuximab vedotin), combined with chemo agents doxorubicin, vinblastine and dacarbazine, for the